Aquestive Therapeutics (NASDAQ:AQST) Insider Sells $141,904.00 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Carl Kraus sold 20,272 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total transaction of $141,904.00. Following the sale, the insider directly owned 282,475 shares in the company, valued at approximately $1,977,325. This trade represents a 6.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Aquestive Therapeutics Stock Up 1.0%

Aquestive Therapeutics stock opened at $7.08 on Monday. The company’s fifty day simple moving average is $5.07 and its 200-day simple moving average is $3.85. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $7.51. The stock has a market cap of $706.02 million, a P/E ratio of -10.11 and a beta of 1.77.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of large investors have recently bought and sold shares of the business. Trust Point Inc. bought a new stake in Aquestive Therapeutics in the third quarter worth $126,000. Cox Capital Mgt LLC bought a new stake in Aquestive Therapeutics during the third quarter valued at about $59,000. Modern Wealth Management LLC bought a new stake in Aquestive Therapeutics during the second quarter valued at about $33,000. BNP Paribas Financial Markets boosted its holdings in Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after acquiring an additional 4,134 shares during the period. Finally, Jane Street Group LLC bought a new stake in Aquestive Therapeutics during the second quarter valued at about $217,000. 32.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on AQST shares. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Oppenheimer boosted their price target on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. JMP Securities upped their price objective on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a report on Thursday, October 9th. Finally, Zacks Research upgraded shares of Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.71.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.